SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001214659-21-013025
Filing Date
2021-12-13
Accepted
2021-12-13 15:58:08
Documents
59
Period of Report
2021-10-31

Document Format Files

Seq Description Document Type Size
1 s12221210.htm   iXBRL 10-Q 1024310
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 8222
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 7915
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 6400
  Complete submission text file 0001214659-21-013025.txt   4461425

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE alzneuro-20211031.xsd EX-101.SCH 44678
6 XBRL CALCULATION FILE alzneuro-20211031_cal.xml EX-101.CAL 39121
7 XBRL DEFINITION FILE alzneuro-20211031_def.xml EX-101.DEF 175399
8 XBRL LABEL FILE alzneuro-20211031_lab.xml EX-101.LAB 286516
9 XBRL PRESENTATION FILE alzneuro-20211031_pre.xml EX-101.PRE 258853
10 EXTRACTED XBRL INSTANCE DOCUMENT s12221210_htm.xml XML 609735
Mailing Address 3802 SPECTRUM BLVD, SUITE C112C TAMPA FL 33612
Business Address 3802 SPECTRUM BLVD, SUITE C112C TAMPA FL 33612 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

IRS No.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-40483 | Film No.: 211488031
SIC: 2834 Pharmaceutical Preparations